Edition:
United Kingdom

Astrazeneca Pharma India Ltd (ASTR.NS)

ASTR.NS on National Stock Exchange of India

1,591.00INR
10:25am GMT
Change (% chg)

Rs-56.10 (-3.41%)
Prev Close
Rs1,647.10
Open
Rs1,656.90
Day's High
Rs1,656.90
Day's Low
Rs1,581.00
Volume
16,403
Avg. Vol
32,269
52-wk High
Rs1,960.00
52-wk Low
Rs919.95

Latest Key Developments (Source: Significant Developments)

Astrazeneca Pharma Receives Import, Market Permission For Osimertinib Tablet
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Astrazeneca Pharma India Ltd ::ASTRAZENECA PHARMA INDIA -GOT IMPORT, MARKET PERMISSION IN FORM 45 FROM DRUGS CONTROLLER GENERAL OF INDIA FOR OSIMERTINIB TABLET 40 MG,80 MG.ASTRAZENECA PHARMA INDIA LTD - OSIMERTINIB TABLET INDICATED FOR FIRST-LINE TREATMENT OF CERTAIN NON-SMALL CELL LUNG CANCERS.  Full Article

Astrazeneca Pharma India says FDC Of XIGDUO XR Tablets Expected To Launch In India In Q4
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Astrazeneca Pharma India Ltd ::FDC OF DAPAGLIFLOZIN + METFORMIN HYDROCHLORIDE FILM COATED TABLETS EXPECTED TO LAUNCH IN INDIA IN Q4 2017-18.  Full Article

Astrazeneca Pharma India Sept-qtr profit surges
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Astrazeneca Pharma India Ltd ::Sept quarter profit 273.8 million rupees.Sept quarter revenue from operations 1.64 billion rupees.Profit in sept quarter last year was 8 million rupees as per ind-as; revenue from operations was 1.39 billion rupees.  Full Article

Astrazeneca Pharma India gets marketing approval for combination of therapies for type 2 diabetes‍​
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Astrazeneca Pharma India Ltd ::Gets marketing approval for Xigduo XR, combination of two anti-diabetic therapies for type 2 diabetes‍​.  Full Article

Indian shares rise as financials rebound, investors cheer fresh trade talks

Aug 17 Indian shares rose on Friday with financials and consumer staples leading the gains, while strong broader Asian peers which cheered Washington and Beijing's decision to hold trade talks next week also boosted investor sentiment.

No consensus analysis data available.